Alnylam Pharmaceuticals
ALNY
#591
Rank
โ‚น2.962 T
Marketcap
โ‚น22,968
Share price
-0.29%
Change (1 day)
62.13%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -โ‚น337.20

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -โ‚น346.77. In 2022 the company made an earnings per share (EPS) of -โ‚น783.82 a decrease over its 2021 EPS that were of -โ‚น607.48.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-โ‚น337.20-56.98%
2022-โ‚น783.8229.03%
2021-โ‚น607.48-3.36%
2020-โ‚น628.58-8.48%
2019-โ‚น686.797.67%
2018-โ‚น637.8639.74%
2017-โ‚น456.4612.94%
2016-โ‚น404.1438.84%
2015-โ‚น291.09-32.88%
2014-โ‚น433.67259.44%
2013-โ‚น120.65-31.25%
2012-โ‚น175.4952.94%
2011-โ‚น114.7530.77%
2010-โ‚น87.75-8.77%
2009-โ‚น96.1878.13%
2008-โ‚น54.00-70.78%
2007-โ‚น184.7899.09%
2006-โ‚น92.81-43.88%
2005-โ‚น165.37-82.33%
2004-โ‚น935.98-59.23%
2003-โ‚น2,296

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-โ‚น143.43-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3,152-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น660.64 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น22.78-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น142.59-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น315.55-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น268.33-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚น168.74-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel